文章名稱引用次數(shù)

• Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease43
• The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease36
• Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease33
• FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac an active immunotherapy against tau protein pathology in Alzheimer's disease25
• Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)23
• Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease20
• The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias20
• The rights of precision drug development for Alzheimer's disease19
• Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice19
• Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph18